Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

Overview of attention for article published in CTS: Clinical & Translational Science, March 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#35 of 1,035)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 9 news outlets

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 9 news stories from 9 outlets.

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Crwe World, 15 Mar 2024

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation…

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Morning Star, 15 Mar 2024

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation…

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Stockwatch, 15 Mar 2024

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation…

News story from Finanz Nachrichten on Friday 15 March 2024

Finanz Nachrichten, 15 Mar 2024

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 5 additional news stories.